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We examined immunity induced by subpatent blood-stage malaria (undetectable by microscopy) using the
rodent malaria parasite, Plasmodium chabaudi chabaudi, postulating that limited infection may allow expansion
of antigen-specific T cells that are normally deleted by apoptosis. After three infections drug cured at 48 h, mice
were protected against high-dose challenge with homologous or heterologous parasites (different strain or
variant). Immunity differed from that generated by three untreated, patent infections. Subpatently infected
mice lacked immunoglobulin G (IgG) to variant surface antigens, despite producing similar titers of total
malaria-specific IgG to those produced by patently infected mice, including antibodies specific for merozoite
surface antigens conserved between heterologous strains. Antigen-specific proliferation of splenocytes har-
vested prechallenge was significantly higher in subpatently infected mice than in patently infected or naive
mice. In subpatently infected mice, lymphoproliferation was similar in response to homologous and heterol-
ogous parasites, suggesting that antigenic targets of cell-mediated immunity were conserved. A Th1 cytokine
response was evident during challenge. Apoptosis of CD4 and CD8 splenic lymphocytes occurred during
patent but not subpatent infection, suggesting a reason for the relative prominence of cell-mediated immunity
after subpatent infection. In conclusion, subpatent infection with blood stage malaria parasites induced
protective immunity, which differed from that induced by patent infection and targeted conserved antigens.
These findings suggest that alternative vaccine strategies based on delivery of multiple parasite antigens at low
dose may induce effective immunity targeting conserved determinants.
In regions where Plasmodium falciparum malaria transmis-
sion is high, individuals eventually acquire nonsterile immu-
nity, where low parasitemia may occur in the absence of clinical
symptoms. Immunity to blood-stage malaria appears to be pre-
dominantly antibody mediated. Transfusion of gamma globulin
from immune adults to children with severe malaria is associ-
ated with reduced parasitemia and clinical improvement (5).
Merozoite surface antigens (2, 6, 32) and variant antigens
expressed on the surface of malaria-infected erythrocytes (in-
cluding PfEMP1) (3, 23) are both targets of protective anti-
body responses.
It is still unclear whether cell-mediated (antibody-indepen-
dent) immune responses play a major role in naturally ac-
quired immunity to blood-stage malaria in humans (reviewed
in reference 9). Loss or suppression of malaria-specific T cells
during the course of natural infection may limit the contribu-
tion of inflammatory T cells to protective immunity. Reduced
numbers of peripheral blood T lymphocytes and diminished
proliferative responses to in vitro stimulation with malarial
antigens are observed during acute P. falciparum infection (15–
17). Animal studies indicate that malaria-specific effector and
helper CD4 T cells are deleted by apoptosis during infection
(12, 41, 42), and this may also be the mechanism in humans (39).
We postulated that limited exposure to blood-stage malaria
may allow the expansion of helper and effector CD4 T cells,
which are normally eliminated during untreated infection. Re-
cently, we showed that repeated exposure of human volunteers
to extremely low doses of P. falciparum induced immunity to a
low-dose challenge with homologous parasites in the absence
of detectable malaria-specific antibodies (31), consistent with
this hypothesis. For ethical reasons, we were unable to chal-
lenge human volunteers with realistic parasite doses or to chal-
lenge with heterologous parasite strains or variants to deter-
mine the specificity of this immunity.
In the present study, we have used the rodent malaria model
Plasmodium chabaudi chabaudi in a resistant mouse strain to
clearly demonstrate that repeated subpatent infection with
blood-stage malaria, drug cured before parasites were detect-
able by microscopy, could induce effective immunity against
high-dose challenge with homologous or heterologous para-
sites. Mice exposed to subpatent infection lacked variant-spe-
cific antibodies but had antibodies to merozoite antigens and
prominent cell-mediated immune responses, and this was as-
sociated with protection of CD4 and CD8 splenic lympho-
cytes from apoptosis that occurred during untreated patent
parasitemia.
MATERIALS AND METHODS
Mice. Female C57BL/6j mice, 8 to 12 weeks old, were obtained from the
Animal Resources Centre (Willeton, Australia). Experiments were approved by
the Institute Ethics Committee.
Parasites. P. c. chabaudi AS and P. c. chabaudi CB were supplied by Richard
Carter, University of Edinburgh (4, 24, 36). Parasites were cryopreserved in
glycerolyte 57 (Baxter Healthcare Corp.). Parasitemias were monitored by per-
forming Giemsa-stained thin tail blood smears.
Infection protocol. Mice were given three intravenous (i.v.) infections with 105
parasitized red blood cells (pRBC) of P. c. chabaudi AS at 4-weekly intervals to
allow drug clearance. Parasites were derived from a single collection during peak
parasitemia in one mouse. For each subpatent infection, mice were drug cured
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48 h after infection (0.2 mg of atovaquone and 0.08 mg of proguanil in 100 l of
water by oral gavage daily for 4 days). Preliminary experiments confirmed that
this protocol was highly effective in preventing the development of microscopi-
cally detectable parasitemia. Control patently infected mice self-cured. Naive
mice were injected with phosphate-buffered saline (PBS) and received drug
treatment at the same time as subpatently infected mice. All mice were drug
treated 15 to 20 days before being subjected to a challenge infection with 106
pRBC.
ELISA. To prepare crude parasite antigen for enzyme-linked immunosorbent
assay (ELISA), blood from mice infected with P. c. chabaudi AS or P. c. chabaudi
CB (30 to 40% parasitemia) was collected, washed in PBS, and incubated with
0.01% (wt/vol) saponin (Aldrich) at 37°C for 20 min. The pellet was washed in
PBS, resuspended in 1.5 ml of PBS, and sonicated.
MaxiSorp Nunc immuno plates, with 96 wells (Nalge Nunc Int.), were coated
overnight at 4°C with 5 or 10 g of parasite antigen per ml in bicarbonate coating
buffer (pH 9.6). The details of the assay have been described previously (13).
Staining variant antigens on the surface of pRBC. The staining procedure was
based on previously described methods (8, 37). Mice were kept in a reverse light
cycle (20:00 h to 08:00 h) for at least 1 week before infection so that late-stage
parasites expressing variant surface antigens could be collected in the morning.
The mice were infected from frozen aliquots of P. c. chabaudi AS (the same
stabilate used during the subpatent infection protocol) or P. c. chabaudi CB. At
10 to 20% parasitemia, the mice were sacrificed at 10:00 h and blood was
collected. After two washes, blood was resuspended at 5% hematocrit in RMPI-
HEPES supplemented with 0.2% (wt/vol) NaHCO3 and 10% fetal calf serum
(FCS) and cultured at 37°C for 3 to 4 h in 5% CO2–5% O2 until late trophozoites
were evident. After three washes in PBS–1% FCS, a 100-l volume of cells (0.2%
hematocrit) was stained using a three-step method and sequentially incubated
with test serum (1/10 dilution), goat anti-mouse immunoglobulin G (IgG) (1/50
dilution; Caltag), and fluorescein isothiocyanate (FITC)-conjugated swine anti-
goat IgG (1/20 dilution; Caltag) plus ethidium bromide (20 g/ml). Incubations
were carried out for 30 min at room temperature, and cells were washed in
PBS–1% FCS between each step. Fluorescence was measured on a FACSCalibur
(BD), and data were analyzed using CellQuest software (BD). Identification of
pRBC in blood from infected mice using DNA-RNA stains is confounded by the
presence of reticulocytes. We overcame this problem by gating on a subpopula-
tion of RBC with higher forward scatter and side scatter that contained a high
proportion of late-stage trophozoites (confirmed by cell sorting) and counted
1,000 events.
Immunofluorescence assay. Late-stage parasites were obtained by culturing as
described above, but for the immunofluorescence assay (IFA), pRBC were
cultured for approximately 8 h until schizonts were visible on a blood smear.
Cells were then washed twice in PBS and resuspended at 1% hematocrit. A 4-l
volume of cells was applied to each well on a 10-well multitest slide (ICN
Biomedicals Inc.) and allowed to dry. The slides were wrapped in a tissue, sealed
inside a plastic bag containing silica beads, and stored at 20°C.
For staining, the slides were fixed in 100% acetone for 10 min. After they were
washed for 10 min in a large volume of PBS, excess PBS was removed and an
ImmEdge pen (Vector Laboratories) was used to draw around individual wells.
After blocking with 80 l of 1% bovine serum albumin (BSA)–PBS for 15 min,
60 l of test serum (diluted 1/100 in 1% BSA–PBS) was added and the mixture
was incubated for 1 h (humid container). The wells were washed five times with
1% BSA–PBS. Texas Red-conjugated goat anti-mouse IgG (heavy plus light
chains) (Jackson ImmunoResearch Laboratories) (1/75 dilution) and Hoechst
(1/500 dilution) in 1% BSA–PBS were added, and the slides were incubated for
1 h in the dark (humid container). The slides were then washed for 10 min in a
large volume of PBS. VectaShield and coverslips were applied, and the slides
were examined by fluorescence microscopy.
Isolation of splenic mononuclear cells. Spleens were harvested, and single-cell
suspensions were prepared. RBC were lysed using Gey’s erythrocyte lysis buffer
(21), and mononuclear cells were isolated by density centrifugation over Nyco-
Prep 1.077 (Axis-Shield PoC AS, Oslo, Norway).
Proliferation assays of splenic mononuclear cells. Spleen cells were diluted to
2  106 cells/ml in culture medium (Eagle’s minimum essential medium [Trace
Scientific] with 5% heat-inactivated FCS, 50 g of streptomycin [CSL] per ml,
100 g of penicillin [CSL] per ml, and 55 M 2-mercaptoethanol [Gibco BRL]),
and 200 l/well was aliquoted into 96-well flat-bottom tissue culture plates
(Corning Life Sciences). Triplicate wells were cultured with concanavalin A
(ConA) (10 g/ml), P. c. chabaudi AS or P. c. chabaudi CB pRBC (2.5  106 to
10  106/ml), or normal mouse RBC adjusted to give equivalent concentrations
of total RBC (from frozen aliquots). After 3 days, the wells were pulsed with 0.25
Ci of [3H] thymidine (NEN) per well for a further 18 to 24 h. The cells were
harvested onto fiberglass filter mats, and radioactivity was measured.
Immunofluorescence staining and flow cytometric analysis of mononuclear
cells. Incubations with monoclonal antibodies were performed on ice in the dark
for 30 min. Cells were washed in PBS–1% FCS–0.05% NaN3. Fluorescence was
measured using a FACSCalibur (BD). Ten thousand events were counted, and
data were analyzed using CellQuest software.
(i) Splenic mononuclear cell subpopulations. Cells were single stained with
CD19-phycoerythrin (PE) (Caltag) or double stained with CD3-FITC (Pharm-
ingen) and CD4-PE (Caltag) or CD3-FITC and CD8-PE (Caltag).
(ii) Annexin V staining. Cells were single stained with CD4-PE, CD8-PE, or
CD19-PE. After two washes, the cells were stained with the Annexin V-Fluos
staining kit (Roche Diagnostics) and washed before being subjected to analysis.
(iii) Intracellular cytokine staining of whole blood. Cells were cultured with
1.32 l of GolgiStop (Pharmingen) per ml with or without 20 ng of phorbol
12-myristate 13-acetate (PMA) (Sigma) per ml and 1 g of calcium ionophore
(Sigma) per ml for 4 h at 37°C by previously described methods (34, 38). The cells
were washed, resuspended in 200 l of culture medium, and stained with CD4-
FITC (Caltag). After lysis of RBC (21), the cells were fixed and permeabilized
using a Cytofix/Cytoperm kit (Pharmingen). Gamma interferon (IFN-)-PE
(Pharmingen), interleukin-4 (IL-4)-PE (Pharmingen), or PE-conjugated isotype-
matched negative control (Pharmingen) diluted 1/50 in PermWash Buffer was
added, and the mixture was incubated for 30 min, washed in fluorescence-
activated cell sorter buffer and analyzed.
Statistical analysis. Protective immunity was determined by comparing peak
parasitemia during challenge. Parasitemia data from two challenge experiments
were pooled for analysis after establishing there were no significant differences
between experiments. Nonparametric tests (Mann-Whitney or Kruskal Wallis)
were used to compare groups (  0.05).
RESULTS
Specificity of immunity induced by subpatent infection.
Mice exposed to three subpatent infections (drug treated 48 hs
postinfection) or three patent infections (self-cured) with P. c.
chabaudi AS, together with naive controls, were challenged
with identical parasites or with a different parasite strain or
variant.
Mice exposed to subpatent infections were protected against
high-dose challenge with homologous parasites compared with
naive mice (mean peak parasitemia  standard error of the
mean, 1.6%  0.7% and 36.5%  1.2%, respectively [P 	
0.001]) (Fig. 1A). However, patent infections induced better
protection against homologous challenge than did subpatent
infections (mean peak parsitemia, 0.02% 0.01% and 1.6%
0.7, respectively [P 	 0.001]). Reduced parasitemia in subpa-
tently infected mice was associated with protection against
overt signs of clinical disease, including ruffled hair and re-
duced activity and, in separate experiments, was shown to
correlate with prevention of significant weight loss (mean
weight loss SEM: 0.7% 1.1% compared with 8.6% 1.5%
for naive mice [P 	 0.01] and 0.002%  1.0% [P  0.6] for
patently infected mice [n  5 per group]).
Following subpatent infection with P. c. chabaudi AS, mice
were also strongly protected against heterologous challenge
with P. c. chabaudi CB, in contrast to naive mice (3.3% 1.4%
and 22.2%  2.9%, respectively [P 	 0.01]) (Fig. 1A). In sub-
patently infected mice, there was no significant difference in
peak parasitemia during homologous (AS) and heterologous
(CB) challenge (P  0.51).
During heterologous challenge with P. c. chabaudi CB, pa-
tently infected mice had significantly lower peak parasitemias
(0.08%  0.03%) than did naive mice (22.2%  2.9% [P 	
0.001]) (Fig. 1A). However, peak parasitemias were modestly
but statistically significantly higher during heterologous (CB)
challenge compared with homologous (AS) challenge (P 	
0.05). Peak parasitemias were significantly higher in subpa-
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tently infected mice than in patently infected mice challenged
with CB parasites (P 	 0.01).
Previous studies have shown that during P. c. chabaudi AS
infection, recrudescent parasites express different variant sur-
face antigens from those expressed by parasites that dominate
the primary peak (25, 26, 30). To compare immunity to para-
sites expressing homologous and heterologous variant surface
antigens, parasites were collected during the primary peak
(“primary variant”) or recrudescent peak (“recrudescent vari-
ant”) of a P. c. chabaudi AS infection in a single mouse and
frozen in multiple aliquots. Three patent and subpatent infec-
tions with primary variant parasites were followed by challenge
with either homologous primary variant or heterologous recru-
descent variant parasites (Fig. 1B). The results were similar to
those from experiments using P. c. chabaudi AS and CB
strains. The results of these experiments collectively showed
that subpatent infections, like patent infections, could induce
heterologous immunity against high-dose challenge with blood
stage malaria parasites.
Magnitude and specificity of the antibody response induced
by subpatent infection. Mice exposed to subpatent or patent
infections with P. c. chabaudi AS had significant titers of IgG
against homologous P. c. chabaudi AS and heterologous P. c.
chabaudi CB antigen by ELISA, compared to naive mice (P 	
0.001) (Fig. 2). Subpatently and patently infected mice had
similar titers of IgG recognizing AS and CB antigen, suggesting
that most IgG was specific for epitopes that were commonly
expressed in both strains.
In sera from subpatently and patently infected mice, immu-
nofluorescence assays of fixed parasites detected IgG that was
bound to the surface of merozoites and other intracellular
antigens in homologous AS and heterologous CB pRBC. This
suggested that conserved merozoite surface antigens were tar-
gets of antibody responses induced by both subpatent and
patent infections (Fig. 3).
Interestingly, subpatently infected mice lacked IgG specific
for variant antigens on the surface of homologous P. chabaudi
AS pRBC (Fig. 4). In contrast, serum from patently infected
FIG. 1. Specificity of immunity induced by subpatent infection. Subpatently and patently mice infected were infected three times i.v. at monthly
intervals with 105 P. c. chabaudi As pRBC. Naive mice were injected i.v. with PBS. Subpatently infected mice were drug cured 48 h postinfection,
and naive mice received the drug at the same time. Patently infected mice were allowed to self-cure. (A) Mice were challenged i.v. with 106
homologous P. c. chabaudi AS or heterologous P. c. chabaudi CB pRBC. Data for individual mice are shown (n  5). This is representative of two
similar experiments. Statistical comparisons between groups are indicated. (B) Mice were challenged i.v. with 106 P. c. chabaudi AS homologous
primary variant parasites or heterologous recrudescent variant parasites (derived from recrudescence in the same donor mouse). Individual mice
are shown (n  4 except where indicated). The cross indicates the death of one mouse. Statistical comparisons between groups are indicated.
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mice had significant levels of IgG that bound to the surface of
AS but not CB live pRBC (P 	 0.01 compared to serum from
naive mice), indicating that these antibodies were variant spe-
cific. Since serum from patently and subpatently infected mice
had similar levels of total IgG by ELISA (Fig. 2), this could not
be attributed to nonspecific binding.
Antigen-specific proliferation of splenic lymphocytes. Spleen
cells collected from mice 6 weeks after the third subpatent
infection with P. c. chabaudi AS (2 weeks after drug treatment)
showed significant antigen-specific proliferation in response to
stimulation with freeze-thawed AS pRBC (Fig. 5A) or CB
pRBC (Fig. 5B) (P 	 0.05 compared with naive mice), sug-
gesting priming of T cells specific for antigens commonly ex-
pressed in both strains. In contrast, proliferation of splenic
lymphocytes collected from patently infected mice (6 weeks
after the third infection, 2 weeks after drug treatment) was not
significantly greater than proliferation of splenic lymphocytes
from naive mice in the presence of AS or CB pRBC. The
proportions of CD3 CD4 and CD3 CD8 splenic lympho-
cytes were not significantly different among naive, patently
infected, and subpatently infected mice (results not shown),
consistent with comparable proliferative responses to ConA
stimulation observed in all groups (Fig. 5). This suggests that
differences in the proliferative responses to malaria parasite
antigen were attributable to differences in the relative numbers
of antigen-specific T cells rather than to a global change in
splenic lymphocyte subpopulations after patent infection.
Cytokine production by peripheral blood lymphocytes. To
characterize the cytokine profile of the dominant CD4 T
lymphocyte population present during challenge, intracellular
cytokine staining was performed on peripheral blood lympho-
cytes collected on day 6 post-challenge (pooled from mice in
each group [n 4]). There were higher proportions of IFN-
than IL-4 CD4 lymphocytes in naive, patently infected, and
subpatently infected mice (Fig. 6), suggesting a predominantly
Th1-type response.
Subpatent infection primed antigen-specific splenic lym-
phocytes without inducing lymphocyte apoptosis. Mice were
given a single infection with 105 P. c. chabaudi AS pRBC. On
day 2, a group of infected mice and naive controls were sacri-
ficed and the splenic lymphocyte subsets (CD4, CD8, and
CD19) were examined for evidence of apoptosis. Antigen-
specific proliferation was also examined. Lymphocytes from
infected mice showed no higher levels of annexin V staining
than did naive mice on day 2 (Fig. 7). Lymphoproliferative
responses to P. c. chabaudi AS antigen were similar in naive
and infected mice (Fig. 7).
From day 2, one group of the remaining mice was drug cured
(subpatent) while another group developed patent parasitemia
(patent). When patently infected mice reached peak para-
sitemia on day 8, both groups, along with naive control mice,
were sacrificed. A significantly higher percentage of CD4 and
CD8 splenic lymphocytes from patently infected mice were
positive by annexin V staining compared with naive mice (P 	
0.05) (Fig. 7). The proportions of CD4 and CD8 lympho-
cytes in the spleen were significantly reduced in patently in-
FIG. 2. Specificity of antibodies induced by subpatent infection,
measured by ELISA. Following three infections with P. c. chabaudi AS
and prior to challenge infection, serum was collected from patently and
subpatently infected mice as well as naive controls (Fig. 1A). Titers of
parasite-specific IgG against homologous P. c. chabaudi AS and het-
erologous P. c. chabaudi CB crude parasite antigens were measured by
ELISA. Reciprocal median IgG titers (and interquartile range) are
shown (n  10). These data are representative of two experiments.
FIG. 3. Specificity of antibodies induced by subpatent infection,
measured by IFA. Serum was collected from naive, patently infected,
and subpatently infected mice prior to the challenge infection (Fig.
1A). Binding of serum IgG to homologous P. c. chabaudi AS (A) and
heterologous P. c. chabaudi CB (B) acetone-fixed schizonts was as-
sessed by immunofluorescent staining with Texas Red-conjugated anti-
mouse IgG and Hoechst (n  10). Representative images are shown.
Similar results were obtained in two separate experiments.
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fected mice compared with the levels in naive mice (P 	 0.05)
(results not shown). The proportion of apoptotic splenic lym-
phocytes in subpatently infected mice was similar to that of
naive controls, and there was no alteration of CD4 and CD8
lymphocyte subsets. Despite limited exposure to blood stage
parasites during a single infection, splenic lymphocytes from
subpatently infected mice showed significant proliferation in
response to all doses of parasite antigen, compared with lym-
phocytes from naive mice (P 	 0.05). In contrast, cells from
patently infected mice showed no greater response to P. c. cha-
baudi AS freeze-thawed pRBC than did cells from naive con-
trol mice, and the response to ConA was significantly lower (P	
0.05), consistent with the reduced proportions of CD4 and
CD8 lymphocytes in the spleen during acute patent infection.
DISCUSSION
We hypothesized that limited blood stage malaria infection
may allow an expansion of antigen-specific CD4 T lympho-
cytes that are normally deleted by apoptosis (12, 41, 42), lead-
ing to a modified but effective immune response. In an earlier
study of human volunteers, three infections with approximately
30 P. falciparum-infected RBC that were drug treated after 8
days generated immunity against a short-term challenge with a
similar number of homologous parasites (31). Here we have
extended these studies by using the mouse malaria model, P. c.
chabaudi, to demonstrate that repeated subpatent blood stage
infection could induce significant protective immunity against
high-dose homologous and heterologous parasite challenge.
Protection against heterologous parasites was almost as effec-
tive as protection against homologous parasites, suggesting
that the main targets of this immunity are conserved antigens.
Consistent with this, lymphoproliferation and IFA data show-
ing responses to both homologous and heterologous antigens
in vitro indicated that antibody and cell-mediated components
of immunity induced by subpatent infection targeted conserved
determinants. Conservation of antigenic targets may reflect the
FIG. 4. Antibodies to variant parasite antigens on the RBC surface.
Serum was collected from naive, patently infected, and subpatently
infected mice prior to challenge infection (Fig. 1A). Binding of serum
IgG to the surface of homologous P. c. chabaudi AS and heterologous
CB pRBC (trophozoite stage) was determined by flow cytometry.
(A) Means and SEMs of the mean fluorescence intensity of FITC
labeling (ethidium bromide-positive cells) are shown for each group of
mice (n  10). These data are representative of two similar experi-
ments. (B) Representative dot plots of AS and CB pRBC stained with
serum, goat anti-mouse IgG, swine anti-goat IgG-FITC, and ethidium
bromide are shown, with the mean fluorescence intensity of FITC
labeling (ethidium bromide-positive cells) indicated.
FIG. 5. Antigen-specific proliferation of splenic lymphocytes. Sub-
patently and patently infected mice were sacrificed after completion of
three infections with P. c. chabaudi AS, together with naive controls.
Splenic lymphocytes from all mice were stimulated for 3 days with
freeze-thawed P. c. chabaudi AS (A) or P. c. chabaudi CB (B) pRBC,
ConA, and freeze-thawed uninfected mouse RBC (nRBC) and pulsed
with [3H] thymidine for a further 18 to 24 h (n  4). This is represen-
tative of two similar experiments.
2482 ELLIOTT ET AL. INFECT. IMMUN.
 o
n
 O
ctober 19, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
absence of immune pressure in a natural setting. Although
there is evidence for selective pressure on preerythrocytic T-
cell epitopes (11), this has not been shown for blood stage
antigenic targets of CD4 T cells.
Despite differences in parasite dose and duration of infec-
tion between the previous study with P. falciparum (31) and the
present study with P. c. chabaudi, there were similarities in the
nature of the immunity induced by limited exposure to blood
stage malaria. In both studies, in vitro correlates of cell-medi-
ated immunity, lymphoproliferation and Th1 cytokine secre-
tion, were prominent. Higher cellular immune responses have
also been observed in children in malaria-endemic areas after
long-term chemoprophylaxis, than in placebo controls (7, 28),
suggesting that our observations with the P. c. chabaudi model
are relevant to human malarial immunity.
Whereas the human volunteers infected with very low doses
of P. falciparum failed to produce detectable malaria-specific
antibodies (31), after subpatent P. c. chabaudi infections mice
produced similar levels of total malaria-specific antibodies to
those in mice exposed to patent infections. However, a striking
feature of immunity induced by subpatent infections with P. c.
chabaudi was the absence of antibodies specific for variant
antigens on the surface of pRBC, suggesting that these pro-
teins are less immunogenic than other malarial antigens. Struc-
turally complex proteins may not undergo optimal antigen
processing and thus may slow the generation of helper CD4
T cell responses (18). Subpatent infection, by reducing antigen
concentrations, may prevent the generation of adequate T-cell
help for effective antibody responses to such proteins (43).
Alternatively, if variant surface antigens are expressed at rel-
atively low levels compared to merozoite antigens, a higher
parasitemia may be necessary to generate a detectable variant
specific antibody response.
Despite their lack of variant-specific antibodies, subpatently
infected mice quickly controlled their parasitemia during high-
dose challenge and were protected against overt clinical signs
of infection, suggesting that variant-specific antibodies are not
necessary for protection against severe disease. The presence
of variant-specific antibodies prechallenge probably explains
why patently infected mice were better protected than subpa-
tently infected mice against homologous challenge.
We explored the mechanism of the modified immune re-
sponse observed after subpatent infections. Adoptive-transfer
FIG. 6. Intracellular cytokine staining of peripheral blood lympho-
cytes day 6 post-challenge. Peripheral blood was collected and pooled
from mice in each group (n  4) on day 6 post-challenge. After a 4-h
stimulation of whole blood with PMA and calcium ionophore, intra-
cellular cytokine staining for IFN and IL-4 production by CD4
lymphocytes was performed. Dot plots from each group are shown.
Numbers indicate the percentage of CD4 lymphocytes producing
each cytokine and nonspecific staining with isotype control monoclonal
antibody.
FIG. 7. A single subpatent infection primed antigen-specific splenic
lymphocytes without inducing lymphocyte apoptosis. Mice were in-
fected with 105 P. c. chabaudi AS pRBC i.v. on day 0. On day 2, the first
group of infected mice was killed, along with naive controls (n  4).
Subpatently infected mice were drug-cured on day 2, while patently
infected mice were allowed to develop detectable parasitemia. Naive,
patently infected, and subpatently infected mice were killed on day 8
(n  4). Apoptosis of splenic lymphocyte subsets was assessed by
staining with annexin V, and proliferation of lymphocytes, stimulated
with freeze-thawed P. c. chabaudi AS pRBC was examined on days 2
and 8. Means and SEM are shown. This is representative of two similar
experiments.
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studies have shown that malaria-specific effector CD4 T cells
(12, 42) and helper CD4 T cells (41) are deleted by apoptosis
during acute infection. This process is antigen specific and does
not affect bystander CD4 T cells specific for unrelated anti-
gens (42). In the present study, apoptosis of CD4 and CD8
splenic lymphocytes associated with patent infection was pre-
vented by drug cure when the infection was at the subpatent
level. Splenocytes harvested after a single subpatent infection
showed significantly higher antigen-specific proliferation than
did those harvested after patent infection. The reduced re-
sponse to ConA observed in patent mice was probably also
attributable to apoptotic deletion of antigen-specific T lympho-
cytes, which would have constituted a large proportion of
splenic T lymphocytes during acute infection. When spleens
were harvested from mice that had experienced three patent
infections, after resolution of infection the responses to ConA
were similar to those of naive and subpatently infected mice,
indicating that T cells specific for nonmalarial antigens were
probably not affected (Fig. 5). It could be argued that apoptosis
of T lymphocytes during patent infection reflects homeostatic
mechanisms (reviewed in references 10 and 22). However,
T-cell responses in patently infected mice were often similar to
those in naive mice, suggesting overcorrection.
Modulation of dendritic cell function or induction of regu-
latory T cells might also affect lymphoproliferation and cyto-
kine secretion after exposure to patent infection. Maturation
of human monocyte-derived dendritic cells in vitro is impaired
by prior exposure to P. falciparum schizonts (40), and blood
stage P. yoelii parasites inhibit the maturation of mouse bone
marrow-derived dendritic cells (27). However, P. c. chabaudi
AS-infected RBC have been shown to directly activate den-
dritic cells in vitro (33), P. c. chabaudi AS infection induces the
maturation of splenic dendritic cells (20), and functional den-
dritic cells are induced in vivo by P. yoelii infection (29). Thus,
it has not been clearly established that dendritic cell function is
impaired during acute malaria infection in vivo (reviewed in
reference 18), and there is certainly no evidence that this
occurs in the P. c. chabaudi model.
Depletion of CD4 CD25 regulatory T cells protects mice
against a lethal strain of P. yoelii, associated with improved in
vitro proliferative responses to parasitized RBC (14). Al-
though regulatory T cells may also have contributed to the
poor proliferative responses of splenocytes from patently in-
fected mice in the present study, our previous observations that
antigen-specific CD4 T cells are deleted during infection (42)
are more consistent with apoptosis as the primary process re-
sponsible for impaired cellular immune responses after patent
infection.
Despite evidence of T-cell apoptosis and impaired antigen-
specific cellular responses after untreated malaria infection,
patently infected mice were still effectively protected against
homologous and heterologous challenge. Although it is well
established that Th1 effector CD4 T cells are required for the
control of parasitemia early in primary P. c. chabaudi infection
(19), these data suggest that inflammatory CD4 T-cell re-
sponses are unlikely to contribute significantly to protection
against repeat infection. In contrast, antibody boosting during
challenge in patently infected mice (results not shown) sug-
gested that antibody responses were preserved, consistent with
the reduced requirements for CD4 T-cell help during sec-
ondary antibody responses (1, 35).
Although subpatently infected mice had increased antigen-
specific T-cell responses, they were not better protected than
patently infected mice. There are two possible explanations.
First, the protective immunity induced by both patent and
subpatent infection is largely mediated by preexisting antibod-
ies and antibodies generated during secondary response to
challenge, and the contribution of antibody-independent cell-
mediated immunity is minor. It is more likely that enhanced
cell-mediated immunity is induced by subpatent infection, as
suggested by our observations, but this is offset by the effects of
reduced antigen exposure on other aspects of immunity. Pro-
tective antibody responses to specific antigens might have been
quantitatively or qualitatively inferior because of limited anti-
gen exposure during subpatent infection, even though total
malaria-specific antibody levels were unaffected.
In conclusion, we have shown that limited exposure to blood
stage parasites is sufficient to induce protective immunity
against homologous and heterologous parasites. Antibodies to
conserved determinants, including merozoite antigens, cou-
pled with a prominent Th1 cell-mediated immune response
contributed to protection. Although the animals were well
protected against challenge, antibodies to variant surface an-
tigens were not detected, suggesting that these antibodies are
not required for immunity to severe disease. The enhanced
cell-mediated immunity induced by subpatent infection was
associated with protection of T lymphocytes from the apoptosis
normally associated with patent infection.
In our previous study of human volunteers (31), the absence
of detectable malaria-specific antibodies probably reflects the
extremely low parasite doses used for immunization. Given the
role of antibody in immunity induced by subpatent infection
with P. c. chabaudi demonstrated in the present study, these
individuals might not have been protected against high-dose
challenge. However, the findings of the present study suggest
that administration of a parasite dose sufficient to induce both
antibody and cell-mediated immunity is protective and largely
targets conserved determinants. Induction of this type of im-
munity by immunizing with low doses of purified antigens from
whole parasites may be an alternative but highly effective vac-
cine strategy. These observations have important implications
for vaccine approaches and understanding of immunity asso-
ciated with different levels of parasite exposure in malaria-
endemic settings.
ACKNOWLEDGMENTS
This project was supported by the National Health and Medical
Research Council, Australia. R.K. received student scholarships from
the Queensland Institute of Medical Research and the Cooperative
Research Centre for Vaccine Technology.
We thank Brendan Crabb for suggesting inclusion of IFA, Tobias
Spielmann for providing technical advice, Michelle Gatton for helping
with statistical analysis, and Xue Qin Liu for providing technical as-
sistance.
REFERENCES
1. Braley-Mullen, H. 1976. Secondary IgG responses to type III pneumococcal
polysaccharide. II. Different cellular requirements for induction and elicita-
tion. J. Immunol. 116:904–910.
2. Branch, O. H., V. Udhayakumar, A. W. Hightower, A. J. Oloo, W. A. Hawley,
B. L. Nahlen, P. B. Bloland, D. C. Kaslow, and A. A. Lal. 1998. A longitudinal
2484 ELLIOTT ET AL. INFECT. IMMUN.
 o
n
 O
ctober 19, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
investigation of IgG and IgM antibody responses to the merozoite surface
protein-1 19-kilodalton domain of Plasmodium falciparum in pregnant
women and infants: associations with febrile illness, parasitemia, and ane-
mia. Am. J. Trop. Med. Hyg. 58:211–219.
3. Bull, P. C., B. S. Lowe, M. Kortok, C. S. Molyneux, C. I. Newbold, and K.
Marsh. 1998. Parasite antigens on the infected red cell surface are targets for
naturally acquired immunity to malaria. Nat. Med. 4:358–360.
4. Carter, R. 1978. Studies on enzyme variation in the murine malaria parasites
Plasmodium berghei, P. yoelii, P. vinckei and P. chabaudi by starch gel elec-
trophoresis. Parasitology 76:241–267.
5. Cohen, S., I. A. McGregor, and S. C. Carrington. 1961. Gamma-globulin and
acquired immunity to human malaria. Nature 192:733–737.
6. Egan, A. F., J. Morris, G. Barnish, S. Allen, B. M. Greenwood, D. C. Kaslow,
A. A. Holder, and E. M. Riley. 1996. Clinical immunity to Plasmodium
falciparum malaria is associated with serum antibodies to the 19-kDa C-
terminal fragment of the merozoite surface antigen, PfMSP-1. J. Infect. Dis.
173:765–769.
7. Geerligs, P. D., B. J. Brabin, and T. A. Eggelte. 2003. Analysis of the effects
of malaria chemoprophylaxis in children on haematological responses, mor-
bidity and mortality. Bull. W. H. O. 81:205–216.
8. Gilks, C. F., D. Walliker, and C. I. Newbold. 1990. Relationships between
sequestration, antigenic variation and chronic parasitism in Plasmodium
chabaudi chabaudi—a rodent malaria model. Parasite Immunol. 12:45–64.
9. Good, M. F. 2001. Towards a blood-stage vaccine for malaria: are we fol-
lowing all the leads? Nat. Rev. Immunol. 1:117–125.
10. Grossman, Z., B. Min, M. Meier-Schellersheim, and W. E. Paul. 2004.
Concomitant regulation of T-cell activation and homeostasis. Nat. Rev. Im-
munol. 4:387–395.
11. Hill, A. V., A. Jepson, M. Plebanski, and S. C. Gilbert. 1997. Genetic analysis
of host-parasite coevolution in human malaria. Philos. Trans. R. Soc. Lond.
Ser. B 352:1317–1325.
12. Hirunpetcharat, C., and M. F. Good. 1998. Deletion of Plasmodium berghei-
specific CD4 T cells adoptively transferred into recipient mice after chal-
lenge with homologous parasite. Proc. Natl. Acad. Sci. USA 95:1715–1720.
13. Hirunpetcharat, C., J. H. Tian, D. C. Kaslow, N. van Rooijen, S. Kumar, J. A.
Berzofsky, L. H. Miller, and M. F. Good. 1997. Complete protective immu-
nity induced in mice by immunization with the 19-kilodalton carboxyl-ter-
minal fragment of the merozoite surface protein-1 (MSP119) of Plasmodium
yoelii expressed in Saccharomyces cerevisiae: correlation of protection with
antigen-specific antibody titer, but not with effector CD4 T cells. J. Immu-
nol. 159:3400–3411.
14. Hisaeda, H., Y. Maekawa, D. Iwakawa, H. Okada, K. Himeno, K. Kishihara,
S. Tsukumo, and K. Yasutomo. 2004. Escape of malaria parasites from host
immunity requires CD4 CD25 regulatory T cells. Nat. Med. 10:29–30.
15. Ho, M., H. K. Webster, S. Looareesuwan, W. Supanaranond, R. E. Phillips,
P. Chanthavanich, and D. A. Warrell. 1986. Antigen-specific immunosup-
pression in human malaria due to Plasmodium falciparum. J. Infect. Dis. 153:
763–771.
16. Hviid, L., J. A. Kurtzhals, B. Q. Goka, J. O. Oliver-Commey, F. K. Nkrumah,
and T. G. Theander. 1997. Rapid reemergence of T cells into peripheral
circulation following treatment of severe and uncomplicated Plasmodium
falciparum malaria. Infect. Immun. 65:4090–4093.
17. Hviid, L., T. G. Theander, Y. A. Abu-Zeid, N. H. Abdulhadi, P. H. Jakobsen,
B. O. Saeed, S. Jepsen, R. A. Bayoumi, and J. B. Jensen. 1991. Loss of
cellular immune reactivity during acute Plasmodium falciparum malaria.
FEMS Microbiol. Immunol. 3:219–227.
18. Langhorne, J., R. A. F, M. Hensmann, L. Sanni, E. Cadman, C. Voisine, and
A. M. Sponaas. 2004. Dendritic cells, pro-inflammatory responses, and an-
tigen presentation in a rodent malaria infection. Immunol. Rev. 201:35–47.
19. Langhorne, J., B. Simon-Haarhaus, and S. J. Meding. 1990. The role of
CD4 T cells in the protective immune response to Plasmodium chabaudi in
vivo. Immunol. Lett. 25:101–107.
20. Leisewitz, A. L., K. A. Rockett, B. Gumede, M. Jones, B. Urban, and D. P.
Kwiatkowski. 2004. Response of the splenic dendritic cell population to
malaria infection. Infect. Immun. 72:4233–4239.
21. MacPherson G. G., M. Wykes, F.-P. Huang, and C. D. Jenkins. 2001. Iso-
lation of dendritic cells from rat intestinal lymph and spleen, p. 29–41. In
S. P. Robinson and A. J. Stagg (ed.), Dendritic cell protocols, vol. 1. Humana
Press, Totowa, N.J.
22. Marrack, P., and J. Kappler. 2004. Control of T cell viability. Annu. Rev.
Immunol. 22:765–787.
23. Marsh, K., L. Otoo, R. J. Hayes, D. C. Carson, and B. M. Greenwood. 1989.
Antibodies to blood stage antigens of Plasmodium falciparum in rural Gam-
bians and their relation to protection against infection. Trans. R. Soc. Trop.
Med. Hyg. 83:293–303.
24. McLean, A. P., F. A. Lainson, A. M. Sharkey, and D. Walliker. 1991. Genetic
studies on a major merozoite surface antigen of the malaria parasite of
rodents, Plasmodium chabaudi. Parasite Immunol. 13:369–378.
25. McLean, S. A., C. D. Pearson, and R. S. Phillips. 1986. Antigenic variation
in Plasmodium chabaudi: analysis of parent and variant populations by clon-
ing. Parasite Immunol. 8:415–424.
26. McLean, S. A., C. D. Pearson, and R. S. Phillips. 1982. Plasmodium
chabaudi: antigenic variation during recrudescent parasitaemias in mice.
Exp. Parasitol. 54:296–302.
27. Ocana-Morgner, C., M. M. Mota, and A. Rodriguez. 2003. Malaria blood
stage suppression of liver stage immunity by dendritic cells. J. Exp. Med. 197:
143–151.
28. Otoo, L. N., E. M. Riley, A. Menon, P. Byass, and B. M. Greenwood. 1989.
Cellular immune responses to Plasmodium falciparum antigens in children
receiving long term anti-malarial chemoprophylaxis. Trans. R. Soc. Trop.
Med. Hyg. 83:778–782.
29. Perry, J. A., A. Rush, R. J. Wilson, C. S. Olver, and A. C. Avery. 2004.
Dendritic cells from malaria-infected mice are fully functional APC. J. Im-
munol. 172:475–482.
30. Phillips, R. S., L. R. Brannan, P. Balmer, and P. Neuville. 1997. Antigenic
variation during malaria infection—the contribution from the murine para-
site Plasmodium chabaudi. Parasite Immunol. 19:427–434.
31. Pombo, D., G. Lawrence, C. Hirunpetcharat, C. Rzepczyk, M. Bryden, N.
Cloonan, K. Anderson, Y. Mahakunkijcharoen, L. Martin, D. Wilson, S.
Elliott, S. Elliott, D. Eisen, J. Weinberg, A. Saul, and M. Good. 2002.
Immunity to malaria after administration of ultra-low doses of red cells
infected with Plasmodium falciparum. Lancet 360:610–617.
32. Riley, E. M., S. J. Allen, J. G. Wheeler, M. J. Blackman, S. Bennett, B.
Takacs, H. J. Schonfeld, A. A. Holder, and B. M. Greenwood. 1992. Naturally
acquired cellular and humoral immune responses to the major merozoite
surface antigen (PfMSP1) of Plasmodium falciparum are associated with
reduced malaria morbidity. Parasite Immunol. 14:321–337.
33. Seixas, E., C. Cross, S. Quin, and J. Langhorne. 2001. Direct activation of
dendritic cells by the malaria parasite, Plasmodium chabaudi chabaudi. Eur.
J. Immunol. 31:2970–2978.
34. Sewell, W. A., M. E. North, A. D. Webster, and J. Farrant. 1997. Determi-
nation of intracellular cytokines by flow-cytometry following whole-blood
culture. J. Immunol. Methods 209:67–74.
35. Silvy, A., C. Lagresle, C. Bella, and T. Defrance. 1996. The differentiation of
human memory B cells into specific antibody-secreting cells is CD40 inde-
pendent. Eur. J. Immunol. 26:517–524.
36. Snounou, G., T. Bourne, W. Jarra, S. Viriyakosol, and K. N. Brown. 1992.
Identification and quantification of rodent malaria strains and species using
gene probes. Parasitology, 105:21–27.
37. Staalsoe, T., H. A. Giha, D. Dodoo, T. G. Theander, and L. Hviid. 1999.
Detection of antibodies to variant antigens on Plasmodium falciparum-in-
fected erythrocytes by flow cytometry. Cytometry 35:329–336.
38. Tayebi, H., A. Lienard, M. Billot, P. Tiberghien, P. Herve, and E. Robinet.
1999. Detection of intracellular cytokines in citrated whole blood or marrow
samples by flow cytometry. J. Immunol. Methods 229:121–130.
39. Toure-Balde, A., J. L. Sarthou, G. Aribot, P. Michel, J. F. Trape, C. Rogier,
and C. Roussilhon. 1996. Plasmodium falciparum induces apoptosis in hu-
man mononuclear cells. Infect. Immun. 64:744–750.
40. Urban, B. C., D. J. Ferguson, A. Pain, N. Willcox, M. Plebanski, J. M.
Austyn, and D. J. Roberts. 1999. Plasmodium falciparum-infected erythro-
cytes modulate the maturation of dendritic cells. Nature 400:73–77.
41. Wipasa, J., H. Xu, A. Stowers, and M. F. Good. 2001. Apoptotic deletion of
Th cells specific for the 19-kDa carboxyl-terminal fragment of merozoite
surface protein 1 during malaria infection. J. Immuno. 167:3903–3909.
42. Xu, H., J. Wipasa, H. Yan, M. Zeng, M. O. Makobongo, F. D. Finkelman, A.
Kelso, and M. F. Good. 2002. The mechanism and significance of deletion of
parasite-specific CD4() T cells in malaria infection. J. Exp. Med. 195:
881–892.
43. Zinkernagel, R. M., and H. Hengartner. 2001. Regulation of the immune
response by antigen. Science 293:251–253.
Editor: J. F. Urban, Jr.
VOL. 73, 2005 IMMUNITY INDUCED BY SUBPATENT INFECTION WITH MALARIA 2485
 o
n
 O
ctober 19, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
